Monte Rosa Therapeutics (GLUE) Current Assets (2020 - 2026)
Monte Rosa Therapeutics (GLUE) posted quarterly Current Assets of $677.5 million for Q1 2026, up 103.91% year-over-year from $332.3 million in Q1 2025, and up 72.32% quarter-over-quarter from $393.2 million in Q4 2025.
Monte Rosa Therapeutics (GLUE) Current Assets (2020 - 2026) Analysis & Trends
Monte Rosa Therapeutics' Current Assets history runs 7 years deep, the most recent figure standing at $677.5 million for Q1 2026.
- In Q1 2026, Current Assets rose 103.91% year-over-year to $677.5 million; the TTM figure through Mar 2026 stood at $677.5 million (up 103.91% YoY), while the FY2025 annual figure was $393.2 million, up 4.17% from the prior year.
- Current Assets for Q1 2026 stood at $677.5 million, up from $393.2 million in the prior quarter.
- The five-year high for Current Assets was $677.5 million in Q1 2026, with the low at $182.9 million in Q3 2023.
- The 5-year median for Current Assets is $295.2 million (2022), against an average of $309.8 million.
- The sharpest annual moves came in 2023 and 2026: Current Assets plunged 38.05% in 2023, then surged 103.91% in 2026.
- Monte Rosa Therapeutics' Current Assets stood at $275.9 million in 2022, then decreased by 14.38% to $236.2 million in 2023, then soared by 59.79% to $377.4 million in 2024, then rose by 4.17% to $393.2 million in 2025, then jumped by 72.32% to $677.5 million in 2026.
- Business Quant data shows GLUE's Current Assets at $677.5 million in Q1 2026, $393.2 million in Q4 2025, and $401.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Monte Rosa Therapeutics | 1.32 Bn | 688.11 Mn | - | 631.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 631.41 Mn |
| Mar 31, 2026 | 677.55 Mn |
| Dec 31, 2025 | 393.19 Mn |
| Sep 30, 2025 | 401.82 Mn |
| Jun 30, 2025 | 299.47 Mn |
| Mar 31, 2025 | 332.28 Mn |
| Dec 31, 2024 | 377.44 Mn |
| Sep 30, 2024 | 251.21 Mn |
| Jun 30, 2024 | 277.90 Mn |
| Mar 31, 2024 | 199.04 Mn |
| Dec 31, 2023 | 236.21 Mn |
| Sep 30, 2023 | 182.91 Mn |
| Jun 30, 2023 | 208.10 Mn |
| Mar 31, 2023 | 240.56 Mn |
| Dec 31, 2022 | 275.89 Mn |
| Sep 30, 2022 | 295.24 Mn |
| Jun 30, 2022 | 297.05 Mn |
| Mar 31, 2022 | 320.37 Mn |
| Dec 31, 2021 | 348.67 Mn |
| Sep 30, 2021 | 370.52 Mn |